ArticleCell & bioscience2018
The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway.
Article in Cell & bioscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Non-coding RNAs as therapeutic targets in cancer and its clinical application.Journal of pharmaceutical analysis · 2024Review
- circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.Journal for immunotherapy of cancer · 2023Article
- The roles of long non‑coding RNAs in renal cell carcinoma (Review).Molecular and clinical oncology · 2023Review
- A multi-cellular molecular signaling and functional network map of C-C motif chemokine ligand 18 (CCL18): a chemokine with immunosuppressive and pro-tumor functions.Journal of cell communication and signaling · 2022Article
- CCL18 Knockdown Suppresses Cell Growth and Migration in Thyroid Cancer.Journal of healthcare engineering · 2022Article
- Sevoflurane inhibits malignant progression of colorectal cancer via hsa_circ_0000231-mediated miR-622.Journal of biological research (Thessalonike, Greece) · 2021Article
- A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021Review
- CircUBXN7 mitigates H/R-induced cell apoptosis and inflammatory response through the miR-622-MCL1 axis.American journal of translational research · 2021Article
- CCL18 in the Progression of Cancer.International journal of molecular sciences · 2020Review
- miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.British journal of cancer · 2020Article
- Molecular subtype classification of papillary renal cell cancer using miRNA expression.OncoTargets and therapy · 2019Article
Corrections and comments
- Retraction · 2023-02-09Concerns/Issues about Image · Euphemisms for Plagiarism · Plagiarism of Image · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/6129191836DFC2B9A940B0CC0A0F84
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs have emerged as critical modulators of carcinogenesis and tumor progression including renal cell carcinoma (RCC). MiR-622 plays as a tumor inhibitor in some types of cancer, however, its role in kidney cancer is unknown. The purpose of the present work is to investigate the functional behaviors and regulatory mechanism of miR-622 in RCC.
resultsWe examined the expression of miR-622 in RCC and adjacent normal tissues and then explored the roles of miR-622. The results of this analysis indicated that miR-622 activity was significantly downregulated in RCC tissues compared with the corresponding normal tissues, so did in RCC cell lines. MiR-622 was associated with RCC aggressiveness. MiR-622 in RCC cells decreased CCL18 expression and suppressed CCL18 activated MAPK signal pathway. Using Western blot and luciferase reporter assays, it was verified that CCL18 was a direct target of miR-622. A specific and inverse correlation between miR-622 and CCL18 expression was found in human RCC samples.
conclusionsThe results demonstrated that miR-622 acted as a tumor-promoting miRNA by targeting CCL18 in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.